User login
Article Type
Changed
in how they maintain board certification.
The new 2-year option developed by the two groups will replace ABIM’s planned 2-year Knowledge Check-In in Medical Oncology that was scheduled to begin in 2020. ASCO membership is not required to follow the 2-year assessment pathway.
“The new assessment pathway is the result of more than 2 years of input and feedback from ASCO members, as well as our desire to collaborate with ABIM because of their recognized expertise in assessments,” ASCO CEO Clifford A. Hudis, MD, said in the statement. “Our dual goals for reshaping the recertification process are to ensure that assessment better reflects the realities of cancer care and recognizes oncologists for their knowledge gained through educational and quality improvement activities.”
Publications
Sections
in how they maintain board certification.
The new 2-year option developed by the two groups will replace ABIM’s planned 2-year Knowledge Check-In in Medical Oncology that was scheduled to begin in 2020. ASCO membership is not required to follow the 2-year assessment pathway.
“The new assessment pathway is the result of more than 2 years of input and feedback from ASCO members, as well as our desire to collaborate with ABIM because of their recognized expertise in assessments,” ASCO CEO Clifford A. Hudis, MD, said in the statement. “Our dual goals for reshaping the recertification process are to ensure that assessment better reflects the realities of cancer care and recognizes oncologists for their knowledge gained through educational and quality improvement activities.”
in how they maintain board certification.
The new 2-year option developed by the two groups will replace ABIM’s planned 2-year Knowledge Check-In in Medical Oncology that was scheduled to begin in 2020. ASCO membership is not required to follow the 2-year assessment pathway.
“The new assessment pathway is the result of more than 2 years of input and feedback from ASCO members, as well as our desire to collaborate with ABIM because of their recognized expertise in assessments,” ASCO CEO Clifford A. Hudis, MD, said in the statement. “Our dual goals for reshaping the recertification process are to ensure that assessment better reflects the realities of cancer care and recognizes oncologists for their knowledge gained through educational and quality improvement activities.”
Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Consolidated Pubs: Do Not Show Source Publication Logo
Use ProPublica